Azacitidine and Oxaliplatin In Treating Patients With Advanced Cancers Relapsed or Refractory to Any Platinum Therapy
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
This phase I clinical trial studies the side effects and the best dose of azacitidine and
oxaliplatin in treating patients with advanced cancers that do not respond to treatment or
have returned after any platinum therapy. Azacitidine is designed to activate (turn on)
certain genes in cancer cells whose job is to fight tumors. Oxaliplatin is designed to block
the growth and spread of new cancer cells, eventually destroying them, by damaging their
deoxyribonucleic acid (DNA). Giving azacitidine with oxaliplatin may kill more cancer cells
and may also reverse resistance to platinum-based drugs.